CSL (CSL.AX) Stock Price
CSL Price
Revenue has compounded at 8.9% per year over the past 19 years to 16.04 B USD. Earnings per share have grown at 11.8% per year over the last 18 years. CSL's net margin stands at -16.4%, down from 21.5% several years earlier. CSL currently offers a dividend yield of about 3.05%. The payout ratio is around 53% of earnings. The dividend has grown at 12.7% per year over the past 19 years. Analysts set a median price target of 143.52 USD, implying 16.7% above the current price. Of 20 analysts, 15 rate the stock a buy — an overall Buy consensus.
CSL stock price
CSL business model & stock analysis
Frequently asked questions about CSL
The business model of CSL Ltd is focused on providing innovative biotherapies and pharmaceutical products to patients worldwide. With a strong commitment to research and development, CSL specializes in developing plasma-derived and recombinant therapies for various medical conditions. The company's portfolio includes immunoglobulins, vaccines, and coagulation factors, among others. CSL operates through its two main business segments, CSL Behring and Seqirus. CSL Behring focuses on developing and manufacturing therapies for rare and serious diseases, while Seqirus is dedicated to producing influenza vaccines. CSL Ltd's business model emphasizes delivering high-quality and life-saving treatments to improve the health and well-being of individuals globally.
CSL Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of CSL Ltd in the market are Biogen Inc., Grifols S.A., and Shire Plc.
CSL Ltd, also known as CSL Limited, is a global biotechnology company headquartered in Australia. Established in 1916, CSL has a rich history of over a century. Originally known as the Commonwealth Serum Laboratories, it transitioned into a private company in 1994. CSL specializes in the research, development, manufacturing, and marketing of innovative biotherapies and vaccines to combat serious medical conditions. With a strong commitment to improving public health, CSL has expanded its operations globally and has become a trusted name in the biopharmaceutical industry. Today, CSL Ltd continues to make significant contributions to healthcare worldwide through its advanced technologies and dedicated team.
CSL Ltd, a renowned Australian biotechnology company, has achieved numerous significant milestones throughout its history. Notably, CSL Ltd successfully developed and marketed first-of-its-kind blood plasma products and vaccines. They introduced the world's first recombinant product derived from human genes, being pivotal in the treatment of hemophilia. CSL Ltd has also made groundbreaking advancements in the field of immunoglobulins, leading to innovative therapies. Furthermore, the company expanded its global presence and became a major player in the biopharmaceutical industry. With its dedication to research, development, and revolutionizing healthcare, CSL Ltd continues to make remarkable contributions to the medical field.
CSL Ltd is primarily present in various countries and regions across the globe. These include Australia, the company's home country where it is headquartered, North America, Europe, and Asia-Pacific. With a strong global presence, CSL Ltd has established itself as a leading biotechnology company, providing innovative and life-saving solutions in the areas of vaccines, plasma therapies, and recombinant products. As a multinational corporation, CSL Ltd has successfully expanded its operations and collaborations internationally, further strengthening its position in the global market.
CSL Ltd represents strong values and a dedicated corporate philosophy. As a global biotechnology company, CSL is committed to enhancing the health and well-being of people worldwide. The company strives for excellence in its operations, focusing on innovation, quality, and patient-centric outcomes. CSL upholds integrity, ethics, and transparency in all aspects of its business, fostering trust with stakeholders. With a mission to save lives and improve patient outcomes, CSL maintains a customer-driven approach, continuously working towards breakthroughs in medical research and development. Through its commitment to these values and corporate philosophy, CSL Ltd demonstrates its dedication to making a positive impact on global healthcare.
Analysts currently set an average price target of 152.75 USD for the CSL stock (median: 143.52 USD), implying +25.0 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the CSL stock: 13 recommend buying, 7 holding and 0 selling.
Converted at the current exchange rate, the CSL share trades at 109.34 EUR (123.01 USD).
The CSL share (CSL.AX) is listed on 7 stock exchanges, including: SIX (Zürich) (CSL.SW), ASX (CSL.AX), Frankfurt (CSJ.F), München (CSJ.MU), Düsseldorf (CSJ.DU), Hamburg (CSJ.HM).
CSL is a global biotechnology company focused on the production of plasma and vaccine products. The company is divided into two divisions: CSL Behring and Seqirus. CSL Behring produces plasma derivatives used to treat life-threatening diseases and disorders such as Alpha-1 antitrypsin deficiency, bleeding disorders, and immune deficiencies. CSL Behring is the third largest producer of plasma derivatives worldwide with production facilities on five continents. Seqirus is the vaccine division of CSL and focuses on the research, development, manufacturing, and marketing of influenza vaccines. The company is the second largest producer of influenza vaccines globally and has production facilities worldwide. Additionally, CSL also produces products in the field of immunosuppression and inflammatory diseases. The company prides itself on meeting some of the highest quality standards in the industry and collaborate closely with patient organizations to promote understanding of the importance of plasma derivatives and vaccines. CSL's business model is based on the research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. CSL's plasma derivatives and vaccines are often life-saving and essential for the health and lives of many people. CSL invests significantly in research and development to develop and improve new products and treatments. The company works closely with government agencies and health organizations to ensure that its products meet the highest standards and are accessible worldwide. To further strengthen its business model, CSL has developed a long-term growth strategy based on innovation, capacity expansion, and geographic expansion. The company will continue to invest in new technologies and research and development to meet the growing demand for life-saving products and treatments. In summary, CSL is a global biotechnology company focused on the production of plasma derivatives and vaccines. The company has two main divisions, CSL Behring and Seqirus, and also produces products in the field of immunosuppression and inflammatory diseases. The business model is based on research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. The company invests significantly in research and development to develop and improve new products and treatments and has developed a long-term growth strategy to meet the growing demand for life-saving products and treatments.
The revenue of CSL is 16.04 B USD. This figure is based on current financial data and reflects the company's business performance.
The profit of CSL is -2.64 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CSL is currently -22.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CSL stock.
The price-to-sales ratio (P/S) of CSL is currently 3.67. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CSL stock.
The Eulerpool Quality Score for CSL is 6/10.
The ISIN of CSL is AU000000CSL8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of CSL is 890952. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of CSL is CSL.AX. The ticker symbol is used to trade CSL shares on the stock exchange.
CSL stock
CSL Peer Group
CSL Ticker
CSL FIGI
All fundamentals and in-depth analysis of CSL
Our stock analysis for CSL stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSL. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.